| Variable | Overall, n(%) | Male, n(%) | Female, n(%) |
| Clinical data |
|
|
|
| Age ≥ 60 years | 42 (66.7) | 21 (63.4) | 21 (70) |
| Obesity | 11 (17.5) | 6 (18.2) | 5 (16.7) |
| Heart Failure data |
|
|
|
| Duration of HF ≥ 36 months | 34 (54) | 23 (69.7) | 11 (36.7) |
| Hospitalisations > 1 in las 12 months | 14 (22.2) | 7 (21.2) | 7 (23.3) |
| Heart Failure with Reduced Ejection Fraction | 33 (52.4) | 17 (51.5) | 16 (53.3) |
| Global Heart Failure | 45 (71.4) | 23 (69.7) | 22 (73.3) |
| NYHA class 3 or 4 | 18 (28.6) | 11 (33.3) | 7 (23.3) |
| Etiology of HF |
|
|
|
| Hypertension Heart Disease | 33 (52.4) | 19 (57.6) | 14 (46.7) |
| Cardiomyopathies | 7 (11.1) | 3 (9.1) | 4 (13.3) |
| Arrhythmia Heart Disease | 7 (11.1) | 4 (12.1) | 3 (10) |
| Ischemic Heart Disease | 4 (6.4) | 2 (6.1) | 2 (6.7) |
| Valvular Heart Disease | 9 (14.3) | 2 (6.1) | 7 (23.3) |
| Congenital Heart Disease | 2 (3.2) | 2 (6.1) | 0 |
| Toxic | 1 (1.6) | 1 (3) | 0 |
| Treatment of Heart Failure |
|
|
|
| ACEI | 18 (28.6) | 6 (18.2) | 12 (40) |
| ARA2 | 9 (14.3) | 4 (12.1) | 5 (16.7) |
| Diuretics | 51 (81) | 28 (84.9) | 23 (76.7) |
| Digoxin | 12 (19.1) | 6 (18.2) | 6 (20) |
| Beta Blockers | 25 (39.7) | 12 (36.4) | 13 (43.3) |
| Calcium Channel Blockers | 12 (19.1) | 8 (24.2) | 4 (13.3) |
| Aspirine | 15 (23.8) | 6 (18.2) | 9 (30) |
| Heparin | 6 (9.5) | 5 (15.2) | 1 (3.3) |